GRAIL is a clinical-stage diagnostics company applying machine learning and next-generation sequencing to early cancer detection. The tech stack is AWS-native (with heavy security layering: WAF, Network Firewall, EDR, XDR, SIEM, SOAR) and Salesforce-heavy across sales, marketing, and service — indicating a B2B2C go-to-market model targeting healthcare systems and primary care practices. Active hiring is heavily skewed toward sales (28 roles) relative to engineering (8), with concurrent projects around territory expansion, payer reimbursement strategy, and primary care onboarding, signaling a shift from product validation toward commercial scale and market access.
Notable leadership hires: Policy and Reimbursement Director, Head of Legal Operations, Account Director
GRAIL develops blood-based diagnostics for early cancer detection, leveraging next-generation sequencing, machine learning, and population-scale clinical data to identify cancer at earlier, more treatable stages. The company is headquartered in Menlo Park, California, with offices in Washington D.C., North Carolina, and the United Kingdom. The organization spans scientists, engineers, and physicians, and operates at 1,001–5,000 employees. Current priorities include scaling adoption of its Galleri test, securing payer coverage, expanding into primary care practices, and building regulatory and reimbursement infrastructure to support clinical deployment and market penetration.
Galleri, a blood-based cancer detection test using next-generation sequencing and machine learning to identify cancer early when treatment outcomes are better.
AWS infrastructure (Direct Connect, Transit Gateway, load balancing, WAF, Network Firewall), Salesforce (Sales Cloud, Service Cloud, Marketing Cloud), Go, React, and enterprise security tools (EDR, XDR, SIEM, SOAR).
Other companies in the same industry, closest in size